Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from AxoGen ( (AXGN) ) is now available.
On January 21, 2026, Axogen entered into an underwriting agreement with Wells Fargo Securities and Mizuho Securities to sell 4,000,000 shares of its common stock at $31.00 per share, with a 30‑day option for underwriters to purchase an additional 600,000 shares, in an offering expected to close on January 23, 2026. The company also signed a payoff letter on January 20, 2026 with its lender Oberland Capital, setting a final payoff amount of about $69.7 million if paid by February 15, 2026, and expects to use a significant portion of the offering’s net proceeds to fully repay and terminate its term loan credit facility, which would release all related liens and strengthen its balance sheet by reducing debt obligations.
The most recent analyst rating on (AXGN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.
Spark’s Take on AXGN Stock
According to Spark, TipRanks’ AI Analyst, AXGN is a Neutral.
The score is driven primarily by improving fundamentals but mixed financial quality: strong revenue and gross-margin profile is tempered by weak cash flow trends and only modest/fragile profitability. Technically, AXGN shows a strong uptrend with supportive momentum indicators. Valuation remains a meaningful drag due to negative earnings and no dividend support, while earnings-call guidance and recent FDA/regulatory progress provide additional upside support.
To see Spark’s full report on AXGN stock, click here.
More about AxoGen
Axogen, Inc., listed on Nasdaq as AXGN, operates in the medical technology and biotechnology sector, specializing in the science, development and commercialization of surgical solutions for peripheral nerve repair. The company’s portfolio includes products such as Avance acellular nerve allografts, Axoguard nerve connectors, protectors and caps, and the Avive+ Soft Tissue Matrix, serving surgeons and healthcare providers through a global network with a focus on making nerve repair the standard of care.
Average Trading Volume: 933,030
Technical Sentiment Signal: Buy
Current Market Cap: $1.47B
Find detailed analytics on AXGN stock on TipRanks’ Stock Analysis page.